SCHEMBL5916571

SCHEMBL5916571

O=c1c2ccccc2[se]n1-c1ccc2ccccc2n1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ METAP2 P50579 6/20 0.54
▸ KDM4E B2RXH2 1/20 0.54
▸ MEN1 O00255 1/20 0.54
▸ QSOX1 O00391 1/20 0.54
▸ RGS12 O14924 1/20 0.54
▸ PMM2 O15305 1/20 0.54
▸ PLIN1 O60240 1/20 0.54
▸ GMNN O75496 1/20 0.54
▸ BBOX1 O75936 1/20 0.54
▸ ALDH1A1 P00352 1/20 0.54
▸ LMNA P02545 1/20 0.54
▸ TP53 P04637 1/20 0.54
▸ CYBB P04839 1/20 0.54
▸ BCHE P06276 1/20 0.54
▸ GLA P06280 1/20 0.54
▸ POLB P06746 1/20 0.54
▸ CYP3A4 P08684 1/20 0.54
▸ CYP2D6 P10635 1/20 0.54
▸ MAPT P10636 1/20 0.54
▸ G6PD P11413 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10747112 0.81 HRH3 (0.40) METAP2KDM4EMEN1QSOX1RGS12
SCHEMBL5917047 0.75 METAP2 (0.56) METAP2KDM4EMEN1QSOX1RGS12
SCHEMBL5916817 0.75 METAP2 (0.56) METAP2KDM4EMEN1QSOX1RGS12
SCHEMBL30530469 0.74 METAP2 (0.57) METAP2KDM4EMEN1QSOX1RGS12
SCHEMBL1353489 0.74 METAP2 (0.57) METAP2KDM4EMEN1QSOX1RGS12
SCHEMBL5916782 0.73 METAP2 (0.61) METAP2KDM4EMEN1QSOX1RGS12
SCHEMBL5916706 0.73 METAP2 (0.61) METAP2KDM4EMEN1QSOX1RGS12
SCHEMBL5916692 0.73 METAP2 (0.51) METAP2KDM4EMEN1QSOX1RGS12
SCHEMBL5916962 0.73 METAP2 (0.54) METAP2KDM4EMEN1QSOX1RGS12
SCHEMBL10352555 0.72 METAP2 (0.54) METAP2KDM4EMEN1QSOX1RGS12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060135569-A1 Use of benzisoselenazolone compounds against ischemic myocardial damage INSTITUTE OF MATERIA MEDICA CHINESE ACADEMY OF MEDICAL SCIENCES (CN) 2006-06-22 — — US claimed
EP-1541145-A1 THE USE OF BENZISOSELENAZOLONE COMPOUNDS AGAINST ISCHEMIC MYOCARDIAL DAMAGE Institute of Materia, Chinese Academy of Medical Sciences (CN) 2005-06-15 — — EP claimed
US-11053236-B2 Substituted isoselenazolone anti-infective, anti-inflammatory, anti-cancer, cytoprotective, neuroprotective, and anti-oxidant agents THE UNIVERSITY OF TOLEDO (US) 2021-07-06 — — US disclosed
US-20190161482-A1 SUBSTITUTED ISOSELENAZOLONE ANTI-INFECTIVE, ANTI-INFLAMMATORY, ANTI-CANCER, CYTOPROTECTIVE, NEUROPROTECTIVE, AND ANTI-OXIDANT AGENTS THE UNIVERSITY OF TOLEDO (US) 2019-05-30 — — US disclosed
WO-2017223160-A1 SUBSTITUTED ISOSELENAZOLONE ANTI-INFLAMMATORY, ANTI-CANCER, CYTOPROTECTIVE, NEUROPROTECTIVE, AND ANTI-OXIDANT AGENTS THE UNIVERSITY OF TOLEDO (US) 2017-12-28 — — WO disclosed
US-20060135569-A1 Use of benzisoselenazolone compounds against ischemic myocardial damage INSTITUTE OF MATERIA MEDICA CHINESE ACADEMY OF MEDICAL SCIENCES (CN) 2006-06-22 — — US disclosed
EP-1541145-A1 THE USE OF BENZISOSELENAZOLONE COMPOUNDS AGAINST ISCHEMIC MYOCARDIAL DAMAGE Institute of Materia, Chinese Academy of Medical Sciences (CN) 2005-06-15 — — EP disclosed
US-4711961-A Benzisoselenazolethiones and process for the treatment of various diseases in humans A. NATTERMANN & CIE GMBH (DE) 1987-12-08 — — US disclosed
US-4550168-A Benzisoselenazolones and a process for the treatment of inflammatory diseases A. NATTERMANN & CIE GMBH (DE) 1985-10-29 — — US disclosed
EP-0154851-A1 Benzisoselenazolethiones,process for their preparation and pharmaceutical products containing these compounds A. Nattermann & Cie. GmbH (DE) 1985-09-18 — — EP disclosed
EP-0100899-A2 Benzisoselenazolones, process for their preparation and pharmaceutical compositions containing them A. Nattermann & Cie. GmbH (DE) 1984-02-22 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060135569-A1 Use of benzisoselenazolone compounds against ischemic myocardial damage TNNI3, TNNT2, MYLK2 METAP2 4321/4885KDM4E 2585/4885MEN1 4647/4885
US-11053236-B2 Substituted isoselenazolone anti-infective, anti-inflammatory, anti-cancer, cytoprotective, neuroprotective, and anti-oxidant agents AIFM1, HSPE1, COX15 METAP2 3120/4885KDM4E 3701/4885MEN1 67/4885
US-20190161482-A1 SUBSTITUTED ISOSELENAZOLONE ANTI-INFECTIVE, ANTI-INFLAMMATORY, ANTI-CANCER, CYTOPROTECTIVE, NEUROPROTECTIVE, AND ANTI-OXIDANT AGENTS AIFM1, HSPE1, COX15 METAP2 3120/4885KDM4E 3701/4885MEN1 67/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback